MMedXYNews
Ask AIHomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY News/Hematology-Oncology

Section

Hematology-Oncology

578 articles

Ask AI
All specialtiesHematology-OncologynewsClinical UpdatesCardiologyOncology

Latest updates

Hematology-Oncology

International Consensus on Management of Soft Tissue and Visceral Leiomyosarcomas: Key Recommendations from the Leiomyosarcoma Global Consensus Group (2026)

An international, evidence-driven consensus harmonizes diagnostic and treatment approaches for soft tissue and visceral leiomyosarcoma, emphasizing multidisciplinary care, site-specific strategies, and priorities for research.

Sep 14, 2026
Hematology-Oncology

Hemoglobin Levels and Mortality Risk: Insights from a Large UK Cohort Study

A UK prospective cohort study reveals a U-shaped association between hemoglobin concentration and mortality, with both low and high levels linked to increased death risk across age and sex groups.

Sep 13, 2026
Hematology-Oncology

Optimizing Bridging Therapy Before BCMA-Directed CAR T-Cell Treatment in Relapsed/Refractory Multiple Myeloma: A Real-World Multicenter Analysis

Bridging therapy before BCMA-directed CAR T-cell infusion in relapsed/refractory multiple myeloma impacts disease control and outcomes. This study analyzes regimen efficacy and safety in 399 patients, highlighting variable responses and saf

Sep 13, 2026
Hematology-Oncology

Evolving Epidemiology and Survival Trends in Myeloproliferative Neoplasms: Insights from SEER 2000-2021

Analysis of SEER data from 2000-2021 reveals incidence, survival trends, and demographic disparities in US patients with myeloproliferative neoplasms, highlighting improved outcomes particularly in primary myelofibrosis and areas for furthe

Sep 13, 2026
Hematology-Oncology

Targeting PRMT9 to Overcome Venetoclax Resistance in AML: A Paradigm Shift in Therapeutic Strategy

PRMT9-mediated arginine methylation drives venetoclax resistance in AML by altering RNA splicing and protein synthesis. Targeting PRMT9 restores venetoclax sensitivity, offering a promising approach to combat resistant AML.

Sep 13, 2026Sign in to read
Hematology-Oncology

Lymph Node Assessment and Survival Outcomes in Favorable Histology Wilms Tumor: Insights from a Large COG Renal Tumor Study

This study evaluates how the number and positivity of lymph nodes affect survival outcomes in over 2,000 patients with stage I–III favorable histology Wilms tumor, underscoring the need for standardized lymph node sampling in surgical stagi

Sep 13, 2026Sign in to read
Hematology-Oncology

Impact of Conditioning Regimens on Pregnancy Outcomes in Female Survivors of Childhood and Adolescent Acute Leukemia: HSCT versus Conventional Chemotherapy

This multicenter study reveals that total-body irradiation (TBI) conditioning before hematopoietic stem cell transplantation severely compromises pregnancy outcomes compared to alkylating agents or conventional chemotherapy in female surviv

Sep 12, 2026
Hematology-Oncology

Impact of Induction Course Number on Outcomes of Allogeneic Stem Cell Transplant with Post-Transplant Cyclophosphamide in AML

This study compares outcomes after allogeneic stem cell transplantation using post-transplant cyclophosphamide in AML patients achieving first remission with one versus two induction courses, revealing similar survival but higher relapse wi

Sep 12, 2026Sign in to read
Hematology-Oncology

Comparative Effectiveness of Azacitidine and Decitabine in TP53-Mutant Acute Myeloid Leukemia: Insights from the COMMAND Registry

This study analyzes outcomes of azacitidine versus decitabine, with or without venetoclax, in TP53-mutant AML, revealing comparable survival outcomes and highlighting the independent prognostic impact of multi-hit TP53 status.

Sep 12, 2026
Hematology-Oncology

Refining Risk Stratification in Newly Diagnosed Multiple Myeloma: Circulating Tumor Cells Identify a Disseminated Genomic High-Risk Phenotype Within IMS-IMWG 2025 Staging

Circulating tumor cells (CTCs) enhance the IMS-IMWG 2025 genomic staging by identifying a disseminated high-risk phenotype in newly diagnosed multiple myeloma, improving prognostic stratification and enabling minimally invasive disease moni

Sep 12, 2026Sign in to read
Clinical Updates

IL-16 Production as a Mechanism of Resistance to BTK Inhibitors and R-CHOP in B-Cell Lymphomas: Mechanistic Insights and Therapeutic Implications

This review synthesizes evidence on IL-16-driven resistance to BTK inhibitors and chemoimmunotherapy in B-cell lymphomas, highlighting the IL-16/CD9/PI3K axis as a targetable epigenetically regulated survival pathway overcoming drug resista

Sep 12, 2026
Hematology-Oncology

Arlocabtagene Autoleucel: Advancing Treatment Paradigms in Heavily Pretreated Relapsed/Refractory Multiple Myeloma

Arlocabtagene autoleucel (arlo-cel) is a novel GPRC5D-targeted CAR T-cell therapy showing promising efficacy and manageable safety in patients with relapsed/refractory multiple myeloma heavily pretreated with standard regimens, including pr

Sep 12, 2026
Hematology-Oncology

TP53 Mutations in Acute Myeloid Leukemia: Impact on Outcomes Post-Allogeneic Hematopoietic Cell Transplantation

TP53 mutations define a high-risk AML subset with inferior survival post-allo-HCT, driven mainly by relapse. Molecular heterogeneity may guide personalized post-transplant strategies.

Sep 10, 2026
Hematology-Oncology

Pre-Transplant KMT2A-PTD Measurable Residual Disease as a Prognostic Biomarker in Acute Myeloid Leukemia Allogeneic Stem Cell Transplantation

The presence of measurable residual KMT2A partial tandem duplication before allogeneic stem cell transplantation in AML significantly predicts poorer survival outcomes, highlighting its potential as a critical MRD biomarker for risk stratif

Sep 10, 2026Sign in to read
Hematology-Oncology

Clonal Hematopoiesis Dynamics in Aplastic Anemia Patients Undergoing Immunosuppressive Therapy: Insights and Clinical Implications

Longitudinal analysis of 371 aplastic anemia patients reveals distinct patterns of clonal hematopoiesis under immunosuppressive therapy, highlighting variable mutation dynamics, cytogenetic changes, and progression risks.

Sep 10, 2026
Hematology-Oncology

CT0590: A Triple-Knockout Allogeneic BCMA CAR T Therapy Advances Treatment in Multiple Myeloma and Plasma Cell Leukemia

CT0590, a novel allogeneic BCMA CAR T-cell therapy armored with NKG2A to resist host NK cell attacks, demonstrates promising safety and efficacy in relapsed/refractory multiple myeloma and plasma cell leukemia, addressing key transplant rej

Sep 10, 2026Sign in to read
Hematology-Oncology

Evaluating Cusatuzumab Combined with Venetoclax ± Azacitidine in Unfit Newly Diagnosed AML: Insights from the Phase Ib ELEVATE Trial

The phase Ib ELEVATE study demonstrates that cusatuzumab combined with venetoclax and azacitidine offers a promising tolerable and effective frontline therapy for patients with newly diagnosed acute myeloid leukemia ineligible for intensive

Sep 9, 2026
Hematology-Oncology

Csnk1a1 E98 Mutations: Metabolic and Signaling Rewiring in del(5q) Myelodysplastic Neoplasms

This study reveals that CSNK1A1 E98 mutations in del(5q) MDS alter kinase signaling and metabolism, creating a stress-tolerant yet inflexible hematopoietic cell state with distinct clinical features and potential therapeutic vulnerabilities

Sep 9, 2026Sign in to read
Hematology-Oncology

Unveiling the Role of snoRNA-Derived RNAs in Hematopoiesis and Acute Myeloid Leukemia Prognosis

This article explores the expression and functional impact of snoRNA-derived RNAs in healthy blood formation and acute myeloid leukemia, highlighting their potential as biomarkers and therapeutic targets.

Sep 9, 2026
Gastroenterology

Targeting Retinoic Acid-Driven CD16hiCD177+ Neutrophils in Steroid-Resistant GI-GVHD: A Novel Therapeutic Avenue

Retinoic acid-driven expansion of CD16hiCD177+ neutrophils mediates steroid-resistant gastrointestinal graft-versus-host disease (GI-GVHD). Inhibition of the retinoic acid receptor restores steroid sensitivity and improves outcomes in murin

Sep 9, 2026
Previous
7 / 25
1…56789…25
Next

Most read

  1. 01Hematology-Oncology

    Precision Immunotherapy in Acute Myeloid Leukemia: Advancing Beyond Traditional Targets

  2. 02Hematology-Oncology

    Targeting MERTK in CLL: A Promising Strategy for Overcoming Ibrutinib Resistance

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.